Health
STAT+: Vertex kidney disease drug scrutinized for infection risk
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
- Published
- (55 min ago)
- Outlet
- STAT News
- Section
- Health
- Length here
- Headline and 20-word snippet. The full article is at the source.
More from STAT News and around the same time
STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptidesAbdul El-Sayed, the Democratic Senate candidate in Michigan, pushes back against the RFK Jr.'s claims, and the new FDA policy around peptides.STAT+: HHS green lights six peptides, despite concerns from FDA scientistsGreat news for peptide fans: The Trump administration is giving the peptide craze a regulatory boost, despite objections from FDA career scientists.Martin Kulldorff critiques scientific gatekeepers at NIH lectureMartin Kulldorff, the biostatistician who advocated against Covid lockdowns, insisted that the rise in measles cases is caused by a widely disputed claim about said lockdowns:STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and moreHHS released a policy that will temporarily allow compounding pharmacies to manufacture some peptide productsSTAT+: New atlas of colorectal tumors sheds light on why cancers in young people are more dangerousA new atlas of colorectal tumors sheds light on why cancers in young people are more dangerous.Opinion: Health care needs buyers willing to say no"The industry’s major players have little appetite for change," writes Anthony T. Lo Sasso.This page holds the headline and a short snippet as published by STAT News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
